

LAURUS LABS COMPLETED THE USFDA INSPECTION OF ITS API FACILITIES UNIT 1 & 3 AT VISAKHAPATNAM.

Hyderabad, August 18, 2017, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010) Laurus Labs Limited, a leading research and development driven pharmaceutical company, has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are only procedural in nature, today.

This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.

About Laurus Labs Ltd.

Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C, Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop Finished Dosage Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.

Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.

Tel: +91 40 3980 4380/+919246564666
Email: mediarelations@lauruslabs.com



DISCLAIMER:

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

AUGUST 18, 2017

Press Release